Your browser doesn't support javascript.
loading
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Castillo, Jorge J; Guerrero-Garcia, Thomas; Baldini, Francesco; Tchernonog, Emmanuelle; Cartron, Guillaume; Ninkovic, Slavisa; Cwynarski, Kate; Dierickx, Daan; Tousseyn, Thomas; Lansigan, Frederick; Linnik, Yevgeny; Mogollon, Renzo; Navarro, Jose-Tomás; Olszewski, Adam J; Reagan, John L; Fedele, Pasquale; Gilbertson, Michael; Grigoriadis, George; Bibas, Michele.
Afiliación
  • Castillo JJ; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Guerrero-Garcia T; Division of Hematology and Oncology, Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, MA, USA.
  • Baldini F; National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy.
  • Tchernonog E; Department of Haematology, CHU Montpellier, Montpellier, France.
  • Cartron G; Department of Haematology, CHU Montpellier, Montpellier, France.
  • Ninkovic S; Department of Haematology, UCLH London, London, UK.
  • Cwynarski K; Department of Haematology, UCLH London, London, UK.
  • Dierickx D; Department of Haematology, University Hospitals Leuven, Leuven, Belgium.
  • Tousseyn T; Department of Haematology, University Hospitals Leuven, Leuven, Belgium.
  • Lansigan F; Division of Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USA.
  • Linnik Y; Division of Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USA.
  • Mogollon R; Department of Medicine, Universidad San Martin de Porres, Lima, Peru.
  • Navarro JT; Catalan Institute of Oncology, German Trias I Pujol Hospital, Badalona, Spain.
  • Olszewski AJ; Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
  • Reagan JL; Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA.
  • Fedele P; Monash Haematology, Monash Medical Centre, Monash University, Clayton, Australia.
  • Gilbertson M; Monash Haematology, Monash Medical Centre, Monash University, Clayton, Australia.
  • Grigoriadis G; Monash Haematology, Monash Medical Centre, Monash University, Clayton, Australia.
  • Bibas M; National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy.
Br J Haematol ; 184(4): 679-682, 2019 02.
Article en En | MEDLINE | ID: mdl-29527667
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Plasmablástico / Bortezomib Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Plasmablástico / Bortezomib Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos